New hope for rare organ-damaging disease: experimental drug enters trials
NCT ID NCT06292780
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 28 times
Summary
This study tests an experimental drug, linvoseltamab, in people with a rare disease called AL amyloidosis that has come back or not responded to other treatments. The drug aims to reduce abnormal proteins that damage organs like the heart and kidneys. About 220 participants will take part to find the best dose and check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY SYSTEMIC LIGHT CHAIN AMYLOIDOSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center
RECRUITINGSeoul, 05505, South Korea
-
City of Hope
RECRUITINGDuarte, California, 91010, United States
-
Clinica Universidad de Navarra - Pamplona
RECRUITINGPamplona, Navarre, 31008, Spain
-
Colorado Blood Cancer Institute/SCRI
RECRUITINGDenver, Colorado, 80218, United States
-
Hospital Universitari Son Espases
RECRUITINGPalma, Balearic Islands, 07120, Spain
-
Hospital de Cabuenes
RECRUITINGGijón, Principality of Asturias, 33203, Spain
-
Karmanos Cancer Institute
RECRUITINGDetroit, Michigan, 48201, United States
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
National and Kapodistrian University of Athens
RECRUITINGAthens, 11528, Greece
-
Ohio State University
RECRUITINGColumbus, Ohio, 43210, United States
-
Roswell Park Comprehensive Cancer Center
RECRUITINGBuffalo, New York, 14263, United States
-
SCRI Oncology Partners
RECRUITINGNashville, Tennessee, 37203, United States
-
Samsung Medical Center
RECRUITINGSeoul, 06351, South Korea
-
Seoul National University Hospital
RECRUITINGSeoul, 03080, South Korea
-
Seoul St. Mary's Hospital - The Catholic University of Korea
RECRUITINGSeoul, 065791, South Korea
-
The Christie NHS Foundation Trust
RECRUITINGManchester, M20 4BQ, United Kingdom
-
University College London Hospitals
RECRUITINGLondon, NW1 2PG, United Kingdom
-
University Hospital La Fe
RECRUITINGValencia, 46026, Spain
-
Universität de Barcelona- Institut d' Investigacions Biomediques August Pi i Sunyer (IDIBAPS)
RECRUITINGBarcelona, 08036, Spain
Conditions
Explore the condition pages connected to this study.